PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Serratiopeptidase significantly improved trismus compared to control on the 4th postoperative day [PMID:33653320]. It improved trismus better than corticosteroids [PMID:29618875].
Serratiopeptidase was effective in reducing swelling from the 2nd to 5th postoperative day [PMID:32855925]. However, a meta-analysis of RCTs found no significant difference in swelling reduction compared to other treatments [PMID:29618875].
Used in the treatment of arthritis, sinusitis, bronchitis, and postoperative swelling [PMID:36291677, PMID:40753267].
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 36291677 (2022) — Serratiopeptidase: An integrated View of Multifaceted Therapeutic Enzyme. · Biomolecules
- 2.PMID: 29404039 (2017) — Analytical techniques for serratiopeptidase: A review. · Journal of pharmaceutical analysis
- 3.PMID: 33134103 (2020) — Serratiopeptidase: Insights into the therapeutic applications. · Biotechnology reports (Amsterdam, Netherlands)
- 4.PMID: 38821483 (2024) — Advances and challenges in serratiopeptidase topical formulation. · Annales pharmaceutiques francaises
- 5.PMID: 32104332 (2017) — The role of serratiopeptidase in the resolution of inflammation. · Asian journal of pharmaceutical sciences